The only downside risks of substantial concern that I can see is generic price deflation and in my opinion this is minimal considering the article below. DOJ action may go against MYX but that is priced in already.
Guidance has not changed and I have topped up once again.
I hope that selling will taper off now that financial year is ended and sellers consolidate losses.
Summary in my opinion: Undervalued. Great buying opportunity. Future growth.
See article below for interesting assessment of future gov pricing regulations of pharma in US medical system.
Let's not forget the U.S.A is the home of vested interests and the power of pharma lobby groups is substantial.
https://www.bloomberg.com/gadfly/ar...-drug-price-promise-seems-likely-to-be-broken
The only downside risks of substantial concern that I can see is...
-
- There are more pages in this discussion • 230 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MYX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$4.71 |
Change
0.070(1.51%) |
Mkt cap ! $400.7M | |||
| Open | High | Low | Value | Volume |
| $4.67 | $4.75 | $4.62 | $953.1K | 203.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1236 | $4.71 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $4.72 | 620 | 1 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| MYX (ASX) Chart |